{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:42:46Z","timestamp":1781880166522,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jdcr.2022.10.040","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:53:49Z","timestamp":1669290829000},"page":"128-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate"],"prefix":"10.1016","volume":"31","author":[{"given":"Justin","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9543-3607","authenticated-orcid":false,"given":"Jeffrey N.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elysha K.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Vandergriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Khosama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S.","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Mauskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2022.10.040_bib1","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1111\/ced.13782","article-title":"Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017","volume":"44","author":"Ma","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"10.1016\/j.jdcr.2022.10.040_bib2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jdcr.2022.10.040_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jdcr.2022.10.040_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/jamadermatol.2018.4070","article-title":"Metastatic calcinosis cutis associated with a selective FGFR inhibitor","volume":"155","author":"Carr","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jdcr.2022.10.040_bib5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cup.13319","article-title":"Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor","volume":"45","author":"Arudra","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.jdcr.2022.10.040_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10637-017-0514-4","article-title":"Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors","volume":"36","author":"Nishina","year":"2018","journal-title":"Invest New Drugs"},{"issue":"16","key":"10.1016\/j.jdcr.2022.10.040_bib7","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jdcr.2022.10.040_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/toxsci\/kft161","article-title":"Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction","volume":"135","author":"Yanochko","year":"2013","journal-title":"Toxicol Sci"},{"issue":"9","key":"10.1016\/j.jdcr.2022.10.040_bib9","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR\u00a0inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jdcr.2022.10.040_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622005136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622005136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:36Z","timestamp":1762475076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622005136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":10,"alternative-id":["S2352512622005136"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.10.040","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor receptor inhibitor therapy induced calcinosis cutis treated with sodium thiosulfate","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.10.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access..","name":"copyright","label":"Copyright"}]}}